Tianeptine oral - Johnson & Johnson

Drug Profile

Tianeptine oral - Johnson & Johnson

Alternative Names: 14C-JNJ-39823277; JNJ-39823277; TPI-1062

Latest Information Update: 10 Apr 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johnson & Johnson
  • Class Irritable bowel syndrome therapies; Small molecules; Thiazepines; Tricyclic antidepressants
  • Mechanism of Action Serotonin uptake stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Major depressive disorder

Most Recent Events

  • 01 Jan 2012 Discontinued - Phase-I for Major depressive disorder in the US and Belgium (PO)
  • 01 Jun 2009 Johnson & Johnson completes a phase I trial in Healthy volunteers in the US (NCT02103985)
  • 30 May 2009 Johnson & Johnson completes a phase I trial in volunteers in Belgium (NCT02049697)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top